Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orthofix Medical Inc. (NASDAQ: OFIX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Orthofix is a global medical technology company focused on spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, and its filings offer detailed insight into these operations.
Orthofix uses current reports on Form 8-K to announce material events such as quarterly financial results, non-GAAP financial measure discussions, and outcomes of its annual meeting of shareholders. Recent 8-K filings describe how the company reports net sales by category, including Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics, and explain non-GAAP measures like constant currency, free cash flow, adjusted gross profit, adjusted net income (loss) and adjusted EBITDA.
Through SEC filings, Orthofix also discloses information on topics such as restructuring costs and impairments related to its M6 artificial disc product lines, merger-related costs associated with SeaSpine, and other adjustments that management excludes when evaluating underlying performance. Governance-related filings, including those covering the annual meeting, document director elections, advisory votes on executive compensation, auditor ratification and board committee appointments.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand segment reporting, non-GAAP adjustments, capital structure details and governance decisions. Users can monitor new 8-Ks and other forms as they are posted to EDGAR, and use the summaries to navigate Orthofix’s financial and regulatory history more efficiently.
Juniper Investment Company and affiliated funds reported an increased ownership stake in Orthofix Medical Inc. common stock. The group now collectively holds 3,784,617 shares, representing approximately 9.6% of Orthofix’s 39,599,959 shares outstanding as of October 31, 2025.
Between October 20, 2025 and February 12, 2026, Juniper Targeted Opportunity Fund, L.P. purchased 541,333 shares in open-market transactions for an aggregate purchase price of approximately $7,916,857, including brokerage commissions. Individual funds within the Juniper complex hold positions ranging from 45,426 shares (about 0.1% of the company) to 2,803,290 shares (about 7.1%).
Juniper Investment Company acts as investment advisor to the funds and may be deemed to beneficially own the full 3,784,617-share position, while Juniper general-partner entities and managing members Alexis P. Michas and John A. Bartholdson may also be deemed beneficial owners, each disclaiming beneficial ownership for purposes other than securities law reporting.
Orthofix Medical Inc.'s CFO Julie Andrews reported a sale of 4,873 shares of common stock on January 16, 2026 at a price of $14.38 per share. This was a Form 4 insider transaction.
According to the footnotes, the shares were sold solely to cover tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, mandatory sell-to-cover arrangement approved by the board’s Compensation and Talent Development Committee. The sale was made without any exercise of discretion by the reporting person.
After this transaction, Andrews beneficially owned 58,039 shares of Orthofix common stock, which includes 45,590 previously reported restricted stock units.
Orthofix Medical Inc. President & CEO Massimo Calafiore reported automatic sales of company stock to cover taxes linked to vesting equity awards. On January 9, 2026, 9,600 shares of common stock were sold at a weighted average price of $15.8235, and on January 12, 2026, 9,797 shares were sold at a weighted average price of $15.2138. The filing explains these transactions were made under a pre-existing, mandated sell-to-cover arrangement approved by the board’s Compensation and Talent Development Committee, with no discretion exercised by the executive. After these sales, Calafiore beneficially owned 217,237 shares of Orthofix common stock, including previously reported deferred stock units and shares acquired under the company’s stock purchase plan.
Orthofix Medical (OFIX) filed its Q3 2025 10‑Q reporting net sales of $205.6 million, up 4.6% year over year, and a net loss of
Cash and cash equivalents were
Orthofix Medical Inc. (OFIX) furnished an update on its business by announcing third‑quarter results for the period ended September 30, 2025 via a press release attached as Exhibit 99.1. The company also furnished an investor relations presentation as Exhibit 99.2. These materials were furnished under Items 2.02 and 7.01 and are not deemed “filed.”
The update outlines non‑GAAP frameworks used by management, including constant currency, free cash flow, adjusted gross profit/margin, adjusted net income (loss), adjusted operating and non‑operating expenses, EBITDA and adjusted EBITDA. It also notes a long‑term normalized effective tax rate assumption of 28% for 2024 and 2025 and lists typical adjustments such as share‑based compensation, merger and restructuring costs, and items related to the discontinued M6 artificial disc product lines.
Juniper-affiliated investors reported a collective 7.2% beneficial stake in Orthofix Medical Inc. The Schedule 13D/A shows Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy together hold 2,845,106 common shares, calculated against 39,494,265 outstanding shares as of the July 31, 2025 record date. Juniper Targeted Opportunity Fund purchased 457,680 shares for approximately $6,357,158 between May 9, 2025 and September 25, 2025, and Juniper Multi-Strategy purchased 18,926 shares for approximately $220,256 between May 8, 2025 and June 17, 2025, all in the open market. The filing states no other contracts or arrangements regarding the shares and disclaims broader third-party rights to dividends or proceeds.
Orthofix Medical Inc. (OFIX) insider transaction: On 08/18/2025 Patrick Fisher, President, Global Orthopedics, sold 1,996 shares of common stock at $14.21 per share to satisfy tax withholding obligations arising from the settlement of restricted stock units. The sale was a pre-existing sell-to-cover action mandated by the Compensation and Talent Development Committee and executed without the reporting person’s discretion. Following the transaction Fisher beneficially owns 30,116 shares, which include 24,936 previously reported restricted stock units and 2,070 shares purchased under the company’s Stock Purchase Plan on 04/30/2025. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared voting and dispositive power over 2,978,000 shares of Orthofix Medical Inc. common stock, equal to 7.54% of the class based on 39,494,265 shares outstanding. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and Mr. Boyd is the managing member of Armistice Capital. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Orthofix Medical Inc. (Nasdaq: OFIX) filed an 8-K on 5 Aug 2025 to furnish, rather than file, its second-quarter 2025 earnings press release (Ex. 99.1) and an investor-relations slide deck (Ex. 99.2). The core 8-K text contains no quantitative results; all GAAP and non-GAAP figures must be obtained from the attached exhibits.
The company reiterates its extensive suite of non-GAAP metrics—constant-currency sales, free cash flow, adjusted gross profit/margin, adjusted operating & non-operating expenses, EBITDA and adjusted EBITDA—and enumerates the permitted adjustments such as share-based compensation, SeaSpine merger costs, litigation, succession charges and M6 product-line restructuring. Management argues these measures enhance period-over-period comparability, yet acknowledges their analytical limitations and provides GAAP reconciliations in the exhibits.
No guidance, outlook or numerical performance data appear in the filing itself; therefore the market impact will depend on figures contained in Exhibit 99.1.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
